OxyContin - Biotech, Pharma and Life Science Channel
OxyContin, an narcotic analgesic produced by Purdue Pharma LP, nets $3m in sales annually, placing it 8th in the world for annual sales.
OxyContin in the brand name for oxycodone, and is similar to morphine. Indications include control of moderate to severe pain, and can be produced in a long-lasting form as well.
Source; Adapted from BioPortfolio.com and Drugs.com
Add the OxyContin News Channel to your RSS reader;
Follow the OxyContin Twitter feed;
News Articles
STAMFORD, Conn., April 26, 2013 /PRNewswire/ -- Purdue Pharma L.P. and Actavis, Inc. announced today that the companies have agreed to resolve the patent infringement lawsuits between them now pending...
Actavis Announces OxyContin® Patent Challenge Settlement
PARSIPPANY, N.J., April 26, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a leading specialty pharmaceutical company, today announced that it has entered into an agreement with Purdue Pharma to...
MIAMI, April 22, 2013 /PRNewswire-USNewswire/ -- Fuisz Pharma today announced its intent to divest its strategic issued patent for the detection of opioid abuse (US 7,214,385 "Pharmaceutical Form...
FLEMINGTON, N.J., April 18, 2013 /PRNewswire/ -- Neura Therapeutik announced today that they will be accelerating the development of their abuse-deterrent brand and generic extended-release opioi...
FDA approves abuse-deterrent labeling for reformulated OxyContin
The U.S. Food and Drug Administration today approved updated labeling for Purdue Pharma L.P.’s reformulated OxyContin (oxycodone hydrochloride controlled-release) tablets. The new labeling indicates...
Osteopathy 'may ease chronic low back pain'
People with chronic low back pain may benefit from visiting an osteopath, according to a recent study in the US.Scientists at the University of North Texas' Health Science Centre assessed 455 adul...
Hands-On Treatment Improves Chronic Low Back Pain, Reduces Medication Use
FORT WORTH, Texas, March 18, 2013 /PRNewswire-USNewswire/ -- The numbers are staggering. More than 632 million people worldwide suffer from low back pain, and it is a leading cause of disability. Acco...
Physician’s Technology Announces New Alternative for Drug Free Pain Treatment
A new report by the Wall Street Journal has Physician’s Technology, LLC stepping up its efforts to remove one billion harmful pills from the streets. Physician’s Tec...
WAISMANN METHOD® Medical Director Expresses Concern about Shift in Opioid Drug Use
BEVERLY HILLS, Calif., Jan. 2, 2013 /PRNewswire/ -- An "abuse-proof" formulation of OxyContin may have helped reduce the number of patients abusing the drug, but Dr. Michael Lowenstein, medical d...
Summit Yields One-of-a-Kind Opportunity To Reduce Prescription Drug Overdoses
Delaware Prescription Drug Abuse Summit Marks a Turning Point in National Epidemic, CLAAD Says. NEWARK, Del., Nov. 16, 2012 /PRNewswire-USNewswire/ --Today, a not-for-profit organization presenti...
Events
None
Companies
None
Clinical Trials
The purpose of this study was to characterize the effectiveness and safety of OROS hydromorphone HCL and OxyContin in patients with chronic osteoarthritis (OA) of the knee or hip who are r...
Preemptive Analgesia With OxyContin Versus Placebo Before Surgery for Long Bone Fractures
We would like to check whether pre-operative administration of an oral controlled-release opioid formulation (Oxycodone hydrochloride (OxyContin)) could result in a clear effect of preempt...
Effective treatment of pain after hip fractures is very important but difficult. It is often an old patient who has many adverse effects with the use of morphine. This is a randomized pil...
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (40 mg) relative to the original OxyContin® (OXY) formulation (40 mg) in the fasted state.
To assess the bioequivalence of reformulated OXY tablets (40 mg) relative to the original OxyContin® (OXY) formulation (40 mg) in the fed state.
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (10 mg) relative to the original OxyContin® (OXY) formulation (10 mg) in the fed state.
The purpose of this study is to compare the subjective and objective effects of Oxymorphone ER (Opana ER) versus Oxycodone CR (Oxycontin).
Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets
The objective of this open-label, randomized, two-period, crossover study was to evaluate the oral bioavailability of the Mallinckrodt controlled-release test tablet formulation of oxycodo...
PubMed Articles
BACKGROUND AND OBJECTIVE: Reformulated OxyContin(®) (oxycodone-HCl controlled release) tablets (ORF) became available in the United States in August 2010. The original formulation of OxyContin(®) (o...
Abstract Objective To compare the cost effectiveness of prolonged release oxycodone/naloxone (OXN) tablets (Targinact*) and prolonged release oxycodone (OXY) tablets (OxyContin†) in patients with mo...
A Comparison of Rural and Urban Nonmedical Prescription Opioid Users' Lifetime and Recent Drug Use.
Background: Nonmedical prescription opioid use has emerged as a major public health concern. The growing burden of nonmedical prescription opioid use in America may have unique manifestations and cons...
Background: Surface electromyographic (sEMG) study of post-tonsillectomy swallow-evoked muscular reactions was performed in order to evaluate the efficacy and safety of oxycodone and dexamethasone in...
Videos
OXYCODONE,OXYCONTIN ADDICTION-GRAPHIC TRAILER FOR TV
THIS PROJECT WAS DONE TO HELP PEOPLE GET SOBER. IT WASNT EDITED PROPERLY AND MISSED A LOT OF WHO I AM, THE GOOD SIDE,----BUT ITS STILL GOTTEN A LOT OF ATTENT...
